相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
F. Coussy et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients
Janos T. Fekete et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
RASAL2 Plays Inconsistent Roles in Different Cancers
Bolun Zhou et al.
FRONTIERS IN ONCOLOGY (2019)
Phosphorylated Rasal2 facilitates breast cancer progression
Xuan Wang et al.
EBioMedicine (2019)
YAP/TAZ Signaling and Resistance to Cancer Therapy
Chan D. K. Nguyen et al.
TRENDS IN CANCER (2019)
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
Siang-Boon Koh et al.
CANCER RESEARCH (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Min Hwan Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Aurora A kinase activates YAP signaling in triple-negative breast cancer
S-S Chang et al.
ONCOGENE (2017)
MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701
Chia-Hung Chen et al.
MOLECULAR ONCOLOGY (2017)
The Mouse Tumor Biology Database: A Comprehensive Resource for Mouse Models of Human Cancer
Debra M. Krupke et al.
CANCER RESEARCH (2017)
NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer
Bhuvaneswari Ramaswamy et al.
CANCER RESEARCH (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype
Qing He et al.
SCIENTIFIC REPORTS (2016)
CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus
Siang-Boon Koh et al.
CANCER RESEARCH (2015)
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells
Monica Rosaria Maiello et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Francesca Zanconato et al.
NATURE CELL BIOLOGY (2015)
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
Xinzhao Wang et al.
ONCOLOGY REPORTS (2015)
RASAL2 activates RAC1 to promote triple-negative breast cancer progression
Min F Feng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy
Sean P. Pitroda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
Sara Koenig McLaughlin et al.
CANCER CELL (2013)
Tackling the Diversity of Triple-Negative Breast Cancer
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
EGFR Tyrosine Kinase Inhibition Worsens Acute Lung Injury in Mice with Repairing Airway Epithelium
Chika Harada et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Chad A. Hall et al.
CANCER RESEARCH (2010)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Eric B. Haura et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
Bryan T. Hennessy et al.
Clinical Proteomics (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition
Heng Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genes that mediate breast cancer metastasis to the brain
Paula D. Bos et al.
NATURE (2009)
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Eric Campeau et al.
PLOS ONE (2009)
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa et al.
CLINICAL CANCER RESEARCH (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCMADR, MDA-MB-231)
Daisuke Takabatake et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Concordance among gene-expression-based predictors for breast cancer
Cheng Fan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sprouty proteins: multifaceted negative-feed back regulators of receptor tyrosine kinase signaling
JM Mason et al.
TRENDS IN CELL BIOLOGY (2006)
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839):: Drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
C Warburton et al.
CLINICAL CANCER RESEARCH (2004)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
